The 30-second answer
KPV is a synthetic tripeptide (Lys-Pro-Val), the C-terminal anti-inflammatory fragment of α-MSH. It has been studied for ~30 years, with multiple independent rodent groups confirming activity in IBD, atopic dermatitis, and corneal wound-healing models, and a molecularly resolved mechanism that hits NF-κB through importin-α blockade rather than melanocortin receptors. There is exactly one human randomized trial, and it tested K(D)PT, the D-isomer, not free-base KPV. The peptide has been FDA Category 2 since 2023, blocking compounding-pharmacy supply. The Pharmacy Compounding Advisory Committee reconsiders that status on July 23-24, 2026: the real near-term inflection point.
Why KPV matters in 2026
In 2023, the U.S. FDA placed KPV in Category 2 on the bulk drug substances list, the "insufficient safety data" tier. The practical effect: 503A and 503B compounding pharmacies cannot legally compound KPV in the United States. Patients and clinicians who had been sourcing KPV through pharmacy channels lost that path overnight; the gray-market research-chemical channel is what remains.
That decision is up for review. The Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026 has KPV (acetate and free base) on the docket for reconsideration. Three outcomes are possible:
- Reclassification to Category 1 (compounding allowed), analogous to what happened with BPC-157 in February 2026. This would re-open the regulated supply path.
- Continuation of Category 2: the prohibition stays.
- Affirmation as Category 3 or stricter: fully unavailable through compounding channels.
Until the PCAC ruling, every legal path for clinical use of KPV in the United States is closed. Every gray-market alternative comes with the usual unregulated-vendor caveats: variable HPLC purity, inconsistent endotoxin levels, products that are sometimes amino-acid blends rather than the actual tripeptide. There is no "right" sourcing answer for KPV right now. There is only "the regulated path is closed; the unregulated path has the quality problems unregulated paths always have."
This combination of a real mechanistic story, a thin clinical evidence base, and a near-term regulatory decision is what makes KPV worth reading about in 2026.
Mechanism: real biology, narrow translation
KPV's mechanistic story is unusually well-resolved for a 3-amino-acid peptide, with three pillars.
PepT1-mediated colon-selective uptake. PepT1 (encoded by SLC15A1) is a di- and tripeptide transporter that is normally restricted to the small intestine. During inflammatory bowel disease flares, PepT1 expression is upregulated on inflamed colonocytes. KPV is a PepT1 substrate, which means it is selectively imported into inflamed colonic tissue while passing through healthy colon largely unaffected. The mechanism was molecularly demonstrated by Dalmasso et al. 2008 and confirmed in Viennois et al. 2016, where PepT1-knockout mice did not respond to oral KPV in a colitis-associated cancer model. This is a genuine "drug-likeness" feature; disease-state-selective delivery is what most engineered targeted-therapy programs are trying to achieve, and KPV gets it for free from its substrate specificity.
NF-κB importin-α/p65RelA blockade. Land 2012 showed that KPV enters the nucleus and competes for the Imp-α3 binding site on the p65RelA subunit of NF-κB, preventing its nuclear translocation and stabilizing IκBα in the cytoplasm. The mechanism was characterized in human bronchial epithelial cells and explains the cytokine suppression observed across keratinocyte, intestinal, and macrophage models; TNF-α, IL-1β, IL-6, IL-8, and iNOS all decrease in a coordinated, NF-κB-dependent fashion.
IL-1β functional antagonism. Haddad 2001 identified sequence overlap between α-MSH(11-13) and IL-1β(193-195), and showed that the D-Pro variant suppresses LPS-induced NF-κB activation in fetal alveolar epithelium. Getting et al. 2003 later confirmed in a crystal-induced peritonitis model that KPV does not bind any of the four melanocortin receptors and does not raise cAMP. The anti-inflammatory effect is preserved in MC1R-null mice. These three independent papers established what KPV is not: a melanocortin agonist. That distinction matters clinically; it separates KPV from Melanotan-2 and afamelanotide (no pigmentation, no appetite effect, no MCR-driven side effects) and confirms that the mechanism is something else.
What is real here: a multi-pathway anti-inflammatory story that converges on NF-κB blockade, with disease-state-selective delivery in IBD. The two reviews most worth reading are Luger & Brzoska 2007 and Brzoska et al. 2008; both predate the recent translational work but remain the comprehensive secondary sources. Sung 2025 extended the story to particulate-stress keratinocytes (PM₁₀-induced apoptosis and pyroptosis), showing the same NF-κB suppression in a distinct stressor.
What is not real: KPV is not a documented mast-cell stabilizer in the KPV-specific literature. The mast-cell claim, repeated across functional-medicine and clinic blogs, has no KPV-specific PubMed paper supporting it. The mast-cell biology belongs to broader α-MSH research, where the mechanism is melanocortin-receptor-mediated; a pathway KPV does not engage. This is a folk claim that has propagated into clinic marketing, and it should be treated as such.
The animal / human evidence gap
The honest read on KPV's evidence base: rich preclinical work, near-empty human evidence.
The preclinical case is real. Multiple independent rodent groups have shown anti-inflammatory activity in DSS and TNBS colitis models with consistent direction of effect; 30-60% reductions in myeloperoxidase activity and histologic score. Kannengiesser et al. 2008 showed effect preservation in MC1R-null mice, ruling out melanocortin signaling as the mechanism. The colitis-associated cancer prevention finding from Viennois 2016 extended the story beyond inflammation to downstream tumorigenesis. Single rabbit and mouse studies of corneal wound healing (Bonfiglio 2006) and traumatic brain injury (Schaible 2013) showed similar direction-of-effect signals.
The human case is one trial; for a different molecule. The single human RCT of any KPV variant is Kucharzik et al. 2017, a Phase IIa multicenter randomized double-blind study of K(D)PT in mild-to-moderate ulcerative colitis. The trial sponsor was Dr. August Wolff GmbH, a German specialty pharma. The primary endpoint was safety; K(D)PT was well tolerated. The efficacy signal was mixed; the primary efficacy analysis was confounded by an unusually high placebo response, with positive subgroup signals on secondary analysis.
The crucial detail: K(D)PT is Lys-D-Pro-Val; the D-isomer of KPV. It is a structurally related but distinct molecule. Hiltz, Catania, and Lipton's 1991 SAR work showed that D-isomer substitutions change activity in measurable ways: D-Lys retains activity, D-Pro alters but does not abolish activity, and D-Val is roughly four times more active than the parent peptide in some assays. Beyond activity, the D-isomer has improved resistance to proteolytic degradation, which is why it was the form chosen for human development. None of this means K(D)PT and free-base KPV are interchangeable. They are sufficiently distinct that the FDA, the trial sponsor, and the publication treat them as separate molecules.
No Phase III follow-up exists. Wolff completed the K(D)PT Phase IIa in 2017 and has not registered a follow-up trial in any indexed registry. Reasons could be commercial (KPV's three amino acids are unpatentable; the commercial path is weak), scientific (the Phase IIa efficacy signal was not strong enough to justify a Phase III bet), or both. Sponsor abandonment is itself a signal; but it is not a definitive one.
For free-base KPV: zero registered trials anywhere. ClinicalTrials.gov, JPRN, CRiS, ChiCTR, and Taiwan's registry all return empty for KPV / Lys-Pro-Val / tripeptide alpha-MSH as of April 2026. The entire human exposure record for free-base KPV is anecdotal community use and historical 503A compounding-pharmacy dispensing prior to 2023.
What people actually use
There are several "KPV doses" floating in conversation. Some are reasonable extrapolations; one is almost certainly a unit error.
| Source | Dose | Route | Notes |
|---|---|---|---|
| Animal IBD models | 1 µg/kg–1 mg/kg | Oral / IP | The dose range nearly all preclinical work uses |
| K(D)PT human Phase IIa | 1.5 mg t.i.d. (4.5 mg/day) | Oral | D-isomer, 4 weeks; not directly transferable |
| Community consensus (gut) | 250–500 mcg/day | Oral capsule | r/Peptides peer-consensus dose |
| Clinic-marketing protocols | 1,000–1,500 mcg/day | Oral | Higher than peer consensus; no validation |
| Topical (compounded) | 0.05–0.5% w/w | Cream | Atopic dermatitis / eczema |
| Injectable (gray-market) | 200–500 mcg/day | SubQ | Less common; vials 5–10 mg |
| AI-generated content | "250 mg twice daily" | Oral | Unit error; inconsistent with 5–10 mg vials |
The "250 mg" figure circulates widely on templated AI-generated review sites and is almost certainly a microgram-to-milligram conversion error that has propagated across cross-scraped content. A real 250 mg/day oral dose would empty a 10 mg vial in roughly an hour, which is incompatible with how the product is sold. Treat any source quoting milligram-per-day oral KPV as suspect.
The walking-the-math step matters. If you want to plug a vial size, a target dose, and a reconstitution volume into the same kind of conversion the peptide reconstitution calculator does, you will land on microgram-scale outputs. We are not telling you what dose to take. We are pointing out that the inputs the calculator accepts produce numbers that the milligram-scale claims do not.
Safety and regulatory
KPV's safety profile reads "benign" in the published record; and the published record is small enough that "benign" should be heard as "no signal in a small dataset," not "characterized as safe."
- FAERS: zero reports for KPV under any alias. This is expected. KPV is not an FDA-approved drug, so consumer FAERS reporting on KPV exposure is effectively nil. Absence of FAERS signal cannot be read as safety.
- K(D)PT Phase IIa: "well tolerated" in the only human trial. The trial duration was four weeks. Any AE that requires N>1,000 or year-plus follow-up to surface remains undetectable.
- Community report base: approximately 100-200 identifiable reports across r/Peptides, Longecity, and MCAS communities. Mild GI upset (3-5% of oral users), injection-site reactions (8-12% of injectors), and orange skin staining from topical formulations are the most-cited side effects. Notably absent from community reports: the mood, sleep, and anxiety changes that show up frequently for BPC-157.
Three specific cautions are worth naming:
NF-κB suppression in undetected malignancy. KPV blocks p65RelA nuclear translocation. NF-κB pathways are dysregulated in many tumors, and the safety implications of generic anti-inflammatory NF-κB suppression in cancer-bearing organisms have not been studied for KPV. Conservative read: contraindicated in active malignancy or history of cancer within five years.
Reproductive safety: unknown. Zero pregnancy, lactation, or fertility data. Default to avoidance during pregnancy and lactation.
Sport and military status. KPV is not specifically named on the WADA Prohibited List, but the S0 catch-all clause (non-approved substances) applies. NCAA carries the same general prohibition. DoD/OPSS classifies non-approved peptides under the prohibited list for service members. For competitive athletes, military service members, and anyone subject to drug testing, treat KPV as risky regardless of its absence from explicit named-substance lists.
The regulatory landscape outside the United States is similarly cautious. EMA has not approved KPV. Australia's TGA defaults KPV to Schedule 4 (prescription only) under the 2023 synthetic-peptide rule. The U.S. PCAC reconsideration on July 23-24, 2026 is the only near-term decision likely to materially change the supply picture in any major jurisdiction.
Frequently asked
Is KPV FDA-approved? No. KPV has been an FDA Category 2 bulk drug substance since 2023; meaning insufficient safety data, and 503A and 503B compounding pharmacies are prohibited from dispensing it. The Pharmacy Compounding Advisory Committee is scheduled to reconsider this designation on July 23-24, 2026; the outcome will determine whether KPV gets a regulated US supply path.
Is the K(D)PT trial human evidence for KPV? Indirectly at best. The Kucharzik 2017 Phase IIa trial in mild-to-moderate ulcerative colitis tested K(D)PT, Lys-D-Pro-Val, the D-isomer with improved proteolytic stability, not the free-base KPV (Lys-Pro-Val) that gray-market vendors sell. The molecules are related but not identical, and the SAR work shows D/L-isomer substitutions change activity. Reading the K(D)PT result as "KPV works in humans" is a category error.
How does KPV differ from Melanotan-2? KPV does not bind melanocortin receptors (MC1R/MC3R/MC4R/MC5R). Three independent papers confirm this: KPV does not raise cAMP, and its anti-inflammatory effect is preserved in MC1R-knockout mice. So KPV does not cause pigmentation, does not produce the appetite or sexual-function effects of MCR agonists, and the "tan" use case people associate with α-MSH analogs does not apply.
Why are people stacking KPV with BPC-157? The community "gut-healing stack" pairs BPC-157 (mucosal angiogenesis and epithelial repair) with KPV (NF-κB inhibition and cytokine suppression) on the theory that the mechanisms are complementary, not overlapping. This is the most popular KPV combination on r/Peptides. There are no human trials of the combination; it is anecdotal practice, not evidence-backed protocol.
Where does the 250 mg dose recommendation come from? It does not come from any human study. The figure circulates on AI-generated "review" sites and is almost certainly a mcg-to-mg unit error that has propagated across templated content. Real community dosing is microgram-scale (250–500 mcg/day oral), which is consistent with vial sizes (5–10 mg total). Treat any source recommending milligram-per-day oral KPV as suspect.
This article reflects the state of the literature as of April 2026. Every PMID was verified live against PubMed before publication by the same INT-01 citation guardrail that gates the calculators on this site. The K(D)PT Phase IIa trial referenced in the body (PMID 28092306) is intentionally not in the article's frontmatter PMID list; the verifier requires compound-name match in PubMed metadata, and that paper indexes under "K(D)PT" rather than "KPV," reflecting the molecular distinction the article spends most of its evidence section explaining.